Validation of Questionnaire and Assessment of Patient Satisfaction for Budesonide/Formoterol Fix Combination Dry Powder Inhalers (DPI) in Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca446 enrolled

Overview

The aim of this study is to describe patient preferences on budesonide/formoterol fix dose combination for the treatment of their COPD, and to find those factors more strongly associated to a better attitude to medication.

Validation of questionnaire and assessment of patient satisfaction for budesonide/formoterol fix combination DPI in COPD

Study Type

OBSERVATIONAL

Enrollment

446

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Provision of subject informed consent and to be an outpatient * Clinical diagnosis of COPD according to ICD-10 classification, females and males, aged ≥ 40 years * To be prescribed a fixed dose combination of inhaled budesonide/formoterol fix combination at least 3 months before the study start Exclusion Criteria: * Pregnancy for women * Use of inhaled medication via a metered dose inhaler (pMDI) * Currently participating in randomized clinical trials and being included in this study once

Locations (20)

Research Site

Adana, Turkey (Türkiye)

Research Site

Afyonkarahisar, Turkey (Türkiye)

Outcomes

Primary Outcomes

Feeling of Satisfaction with Inhaler (FSI-10) Questionnaire in COPD Turkish population.

The FSI-10 is a self-completed 10-item questionnaire to assess patient opinions regarding ease or difficulty of use, portability, and usability of devices for delivery of inhaled medications. Each of the 10 items has 5 response options from poorer to greater ease of use, scored 1 to 5, respectively. The minimum score is 10 whereas the maximum is 50.